Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (M22)

This study has been completed.
PRA Health Sciences
Information provided by (Responsible Party):
Acorda Therapeutics Identifier:
First received: February 26, 2013
Last updated: February 26, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)